Free Trial

Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of "Moderate Buy" by Analysts

Pyxis Oncology logo with Medical background

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) have been given an average rating of "Moderate Buy" by the five research firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $9.00.

Several analysts have issued reports on the company. Royal Bank of Canada restated an "outperform" rating and issued a $8.00 price objective on shares of Pyxis Oncology in a research note on Wednesday, March 19th. HC Wainwright reiterated a "buy" rating and issued a $5.00 price objective on shares of Pyxis Oncology in a report on Monday, May 19th.

Read Our Latest Research Report on Pyxis Oncology

Pyxis Oncology Stock Performance

NASDAQ PYXS traded down $0.01 during trading hours on Thursday, hitting $1.22. 101,802 shares of the company traded hands, compared to its average volume of 739,420. The business's 50-day moving average is $1.06 and its 200-day moving average is $1.50. The stock has a market capitalization of $75.33 million, a price-to-earnings ratio of -1.19 and a beta of 1.15. Pyxis Oncology has a twelve month low of $0.83 and a twelve month high of $5.39.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last issued its earnings results on Thursday, May 15th. The company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.06). Analysts predict that Pyxis Oncology will post -1.04 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in PYXS. ProShare Advisors LLC acquired a new position in Pyxis Oncology in the 4th quarter valued at $26,000. Ameriprise Financial Inc. bought a new position in shares of Pyxis Oncology in the 4th quarter valued at $35,000. Caption Management LLC bought a new position in shares of Pyxis Oncology in the 4th quarter valued at $35,000. Commonwealth Equity Services LLC raised its holdings in shares of Pyxis Oncology by 61.5% during the 4th quarter. Commonwealth Equity Services LLC now owns 26,250 shares of the company's stock worth $41,000 after buying an additional 10,000 shares in the last quarter. Finally, Graham Capital Management L.P. bought a new stake in shares of Pyxis Oncology during the 4th quarter worth $47,000. Institutional investors and hedge funds own 39.09% of the company's stock.

Pyxis Oncology Company Profile

(Get Free Report

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.

Read More

Analyst Recommendations for Pyxis Oncology (NASDAQ:PYXS)

Should You Invest $1,000 in Pyxis Oncology Right Now?

Before you consider Pyxis Oncology, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pyxis Oncology wasn't on the list.

While Pyxis Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines